Crestline Management, LP Adverum Biotechnologies, Inc. Transaction History

Crestline Management, LP

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 12, 2022	SELL	$0.81 - $1.34 $679 - $1,124	-839 Reduced 1.28%	64,854 $78,000
Q1 2022 May 16, 2022	BUY	$1.23 - $1.95 $80,802 - $128,101	65,693 New	65,693 $86,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Crestline Management, LP, based on Form 13F filings with the SEC.

Stay updated on Crestline Management, LP with notifications on news.